ArticleScientific reports2025
Transcription factor CEBPA suppresses sepsis induced lung injury by activating SIRT4 transcription.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the roles of the transcription factor CEBPA and the sirtuin family protein SIRT4 in sepsis-induced acute lung injury (ALI) through both cell-based experiments and animal models. Following LPS or sepsis treatment, both CEBPA and SIRT4 levels were significantly elevated, with a strong correlation observed between these proteins across various samples. Overexpression of CEBPA or SIRT4 mitigated LPS-induced damage, promoting cell survival, reducing apoptosis, and attenuating lung inflammation and injury. In mouse models of ALI, increased expression of CEBPA and SIRT4 substantially alleviated lung injury and inflammation, whereas silencing these genes exacerbated the condition. Further analysis revealed that CEBPA directly binds to the SIRT4 promoter, thereby enhancing SIRT4 protein expression, which in turn amplifies their protective effects. This study is the first to establish a functional link between CEBPA and SIRT4 in ALI, providing novel insights for the development of therapeutic strategies targeting inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.